APA (7th ed.) Citation

PN, T., FS, L., S, R., KM, S., M, G., N, A., . . . EM, R. (2026). Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): A phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 25(2), 147. https://doi.org/10.1016/S1474-4422(25)00426-0

Chicago Style (17th ed.) Citation

PN, Tariot, et al. "Safety and Efficacy of Crenezumab in Cognitively Unimpaired Carriers of the PSEN1Glu280Ala Mutation at Risk for Autosomal-dominant Alzheimer's Disease in Colombia (API ADAD Colombia Trial): A Phase 2, Randomised, Double-blind, Placebo-controlled Trial." The Lancet. Neurology 25, no. 2 (2026): 147. https://doi.org/10.1016/S1474-4422(25)00426-0.

MLA (9th ed.) Citation

PN, Tariot, et al. "Safety and Efficacy of Crenezumab in Cognitively Unimpaired Carriers of the PSEN1Glu280Ala Mutation at Risk for Autosomal-dominant Alzheimer's Disease in Colombia (API ADAD Colombia Trial): A Phase 2, Randomised, Double-blind, Placebo-controlled Trial." The Lancet. Neurology, vol. 25, no. 2, 2026, p. 147, https://doi.org/10.1016/S1474-4422(25)00426-0.